Press releases
- Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
- China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
- Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
- Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
- FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
- Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
More ▼
Key statistics
On Friday, Astellas Pharma Inc (4503N:MEX) closed at 204.11, 0.00% below its 52-week high of 204.11, set on Jan 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 204.11 |
---|---|
High | 204.11 |
Low | 204.11 |
Bid | 205.00 |
Offer | -- |
Previous close | 204.11 |
Average volume | -- |
---|---|
Shares outstanding | 1.81bn |
Free float | 1.81bn |
P/E (TTM) | 161.10 |
Market cap | 2.74tn JPY |
EPS (TTM) | 9.40 JPY |
Annual div (ADY) | 7.65 MXN |
---|---|
Annual div yield (ADY) | 3.75% |
Div ex-date | Mar 27 2024 |
Div pay-date | Jun 03 2024 |
Data delayed at least 20 minutes, as of Jan 12 2024 11:30 GMT.
More ▼